Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.37 |
| ▸ | TSHR | P16473 | 6/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884779 | 0.80 | HCAR2 (0.36) | — | |
| Dimethylformamide SCHEMBL28802744 | 0.80 | KDM4E (0.32) | HSD17B10ALDH1A1ALOX15KDM4E | |
| SCHEMBL14311954 | 0.79 | ADORA3 (0.32) | TSHR | |
| SCHEMBL28331832 | 0.78 | MAPK1 (0.36) | ALDH1A1KDM4EGLA | |
| SCHEMBL30717979 | 0.75 | TP53 (0.35) | HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL30717975 | 0.75 | TP53 (0.35) | HSD17B10ALDH1A1ALOX15 | |
| SCHEMBL18996006 | 0.69 | GABRG2 (0.30) | — | |
| SCHEMBL10847028 | 0.67 | CYP1A2 (0.36) | CYP1A2CYP3A4TSHRCYP2D6HSD17B10 | |
| SCHEMBL13200098 | 0.66 | — | — | |
| SCHEMBL30702431 | 0.65 | HSP90AA1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-120092003-A | CDK protein degrading agents, pharmaceutical compositions and therapeutic uses | 拜欧斯瑞克斯公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-102869358-B | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6(CDK4/6) inhibitor and an mTOR inhibitor for the treatment of cancer | NOVARTIS AG (CH) | 2016-03-23 | — | — | CN | disclosed |
| EP-2536730-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | Novartis AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |